Ge Chang-jiang, Yuan Fei, Feng Li-xia, Lv Shu-zheng, Liu Hong, Song Xian-tao, Chen Xin, Huo Yong
Department of Cardiology, Beijing Anzhen Hospital, Capital Medical University, Beijing, 100029, China.
Chin J Integr Med. 2014 Feb;20(2):88-93. doi: 10.1007/s11655-013-1580-x. Epub 2013 Dec 13.
To study the changes of adenosine diphosphate (ADP)-induced platelet aggregation rate, and evaluate the effects of Maixuekang Capsule (, MKC) on platelet aggregation rate and long-term prognosis of patients with acute coronary syndrome after percutaneous coronary intervention (PCI).
A total of 236 patients with acute coronary syndrome, who received successful PCI, were randomly assigned to a trial group (116 cases) and a control group (120 cases) according to random numbers; treatment allocation occurred when the participants met the inclusion criteria and signed the informed consent forms. In the trial group, the patients were treated with MKC combined with routine medication, and in the control group the patients were treated with routine medication. The therapeutic course for the two groups was 12 months and the follow-up was 12 months. The levels of ADP-induced platelet aggregation rate and serum high-sensitive C-reactive protein (hs-CRP) were determined before PCI, 12 h and 30 days after PCI. In the meantime, the incidence of cardio-/cerebrovascular events was recorded during the 12-month follow-up.
Compared with before PCI, the levels of ADP-induced platelet aggregation rate and serum hs-CRP were significantly higher at 12 h after PCI (P<0.05). They were significantly reduced after 30-day-treatment of MKC, showing statistical differences when compared with those in the control group (P<0.05). During the 12-month follow-up, the incidence of cardio-/cerebrovascular events was significantly lower in the trial group than in the control group (6.9% vs. 12.5%, P<0.01).
ADP-induced platelet aggregation function was significantly elevated after PCI. MKC improved the prognosis of patients with acute coronary syndrome, possibly through inhibiting the platelet aggregation, fighting against inflammation, and protecting the vascular endothelial function.
研究二磷酸腺苷（ADP）诱导的血小板聚集率变化，评价脉血康胶囊（MKC）对急性冠状动脉综合征患者经皮冠状动脉介入治疗（PCI）后血小板聚集率及远期预后的影响。
选取236例成功接受PCI的急性冠状动脉综合征患者，按随机数字法分为试验组（116例）和对照组（120例）；当参与者符合纳入标准并签署知情同意书时进行治疗分配。试验组患者采用MKC联合常规药物治疗，对照组患者采用常规药物治疗。两组疗程均为12个月，随访12个月。分别于PCI术前、术后12小时及30天测定ADP诱导的血小板聚集率及血清高敏C反应蛋白（hs-CRP）水平。同时记录12个月随访期间心脑血管事件的发生率。
与PCI术前比较，PCI术后12小时ADP诱导的血小板聚集率及血清hs-CRP水平显著升高（P<0.05）。MKC治疗30天后上述指标显著降低，与对照组比较差异有统计学意义（P<0.05）。12个月随访期间，试验组心脑血管事件发生率显著低于对照组（6.9%比12.5%，P<0.01）。
PCI术后ADP诱导的血小板聚集功能显著升高。MKC可能通过抑制血小板聚集、抗炎及保护血管内皮功能改善急性冠状动脉综合征患者的预后。
